Baseline Comorbidities in a Population-Based Cohort of Rheumatoid Arthritis Patients Receiving Biological Therapy: Data from the Australian Rheumatology Association Database. (19th August 2009)

• Record Type: Journal Article
• Authors: Briggs, Andrew M.; March, Lyn; Lassere, Marissa; Reid, Christopher; Henderson, Lyndall; Murphy, Bridie; van den Haak, Rosemarie; Rischin, Adam; Staples, Margaret; Buchbinder, Rachelle
• Other Names: Matteson Eric Academic Editor.
• Is Part Of: International journal of rheumatology. Volume 2009(2009)
• Publication Date: 2009-08-19
• Subjects: Rheumatology -- Periodicals; Rheumatology; Rheumatology; Electronic journals; Periodicals; Periodicals; 616.723
• DOI: 10.1155/2009/861481
• Languages: English
• ISSNs: 1687-9260

Abstract

Abstract : Aims . To describe the baseline characteristics of an Australian population-based cohort of rheumatoid arthritis (RA) patients commencing biological therapy. Methods . Descriptive analysis from the Australian Rheumatology Association Database (ARAD). Results . Up to October 2006, there were 681 RA patients taking biologics enrolled in ARAD. Baseline data were available for 624 (72% female, mean (SD) age 57.0 (12.5) years). Of these, 59.5% reported at least one comorbid condition, most commonly hypertension (35.7%) and osteoporosis (30.4%); 61 (9.8%) had a history of malignancy (35 nonmelanoma skin, 5 breast, 4 bowel, 5 cervix, 3 melanoma, 3 prostate and 1 each of lip, lung, myeloma, testis, uterus, vagina). Self-reported infections within the previous 6 months were common (71.5%). Conclusions . History of comorbidities, including recent infections, is common among Australian RA patients commencing biologics, and 10% have a history of malignancy. This may impact future evaluations of health outcomes among this population, including attribution of adverse events of biologic therapy.